Food and Drug Administration's quest to address the growing opioid crisis is hurting many pharmaceutical companies, including Endo International plc - Ordinary Shares (NASDAQ: ENDP), presenting an opportunity for companies like Alkermes Plc (NASDAQ: ALKS), which makes treatments for opioid addictions.
Tom Price, secretary of the health and human services, said last month that products like Alkermes' Vivitrol could be front-and-center in the treatment of opioid addictions, the New York Times reported.
Specifically, there hasn't been a single study, which compares Vivitrol to less expensive competitors and some of the published studies found that participants returned to opioid use while taking Vivitrol.
A study of 250 patients in Russia, which was vital in securing the FDA's approval of Vivitrol for opioid addiction rather than just alcoholism, not only found that nearly half of the patients failed to stay abstinent but some who received a placebo remained in treatment for longer periods.
This is a problem for Alkermes, which may be pitching Vivitrol to investors as being a miracle drug, the New York Times said.